Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.
Checked against the public recordLast updated Mar 5, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Louisville
- Interventions being studied
- Drug: Oxaliplatin; Drug: Capecitabine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * histologically proven non-small cell lung cancer * inoperable Stage III A or B NSCLC * must have measurable disease by RECIST criteria * no more than one prior chemotherapy for advanced disease * ECOG Performance Status of 0, 1, or 2 * must be able to swallow pills or have a working gastric feeding tube and no evidence of malabsorption * negative serum beta-HCG test and under active contraception (for females of childbearing potential) * no known allergies to any of the study drugs * willingness to sign an informed consent Exclusion Criteria: * women who are pregnant or breastfeeding * ANC of less than 1500/mm3 * platelet count of less than 100,000/mm3 * estimated creatinine clearance of less than 50 cc/min (as measured by the Cockcroft-Gault equation) * bilirubin of less than 2mg/dl * SGPT of greater than 2x nl * peripheral neuropathy of Grade 2 or higher * more than one previous chemotherapy and previous radiation therapy to the chest * a history of CHF/MI or other significant cardiac history within the last six months
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- James Graham Brown Cancer CenterLouisville, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2018. Always confirm current availability with the study team.